Holen Sie sich die Stockscreener-App
1.81
1.69%
0.03
Handel nachbörslich:
1.78
-0.03
-1.66%
Schlusskurs vom Vortag:
$1.78
Offen:
$1.8
24-Stunden-Volumen:
142.49K
Relative Volume:
0.06
Marktkapitalisierung:
$3.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.5552
EPS:
-3.26
Netto-Cashflow:
$-6.14M
1W Leistung:
+0.00%
1M Leistung:
+24.83%
6M Leistung:
-45.48%
1J Leistung:
-47.13%
1-Tages-Spanne:
$1.7579
$1.83
1-Wochen-Bereich:
$1.7401
$1.9045
52-Wochen-Spanne:
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.81 | 3.61M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com
Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - Longview News-Journal
Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World
Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus
Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India
GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus
GLMD: Galmed's Aramchol Boosts Cancer Drug Efficacy in Early Studies | GLMD Stock News - GuruFocus
Galmed Pharmaceuticals Unveils Promising Oncology Study Results with Aramchol - TipRanks
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus
GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Understanding GLMD stock ratios for better investment decisions - uspostnews.com
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com
Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks
Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Galmed partners with VCU to target drug resistance - The Pharma Letter
Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire
Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks
Galmed reports key biomarkers for heart and liver health - Investing.com
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):